LOC-paclitaxel

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameLOC-paclitaxel
Drug Alias Name2-linoleyl carbonate-paclitaxelLOC-PacLOC-paclitaxel
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsTubulin inhibitorsMitosis inhibitors +[4] 
TargetsApoptosis regulator Bcl-2Platelet-derived growth factor receptorTubulin
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterAmerican Regent Inc
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A